If this trend holds steady, the sector is on track for an $8.4B year, and may even top 2018's record-breaking annual funding total.
The market is seemingly slowing down, but both companies see other reasons to be optimistic about digital health investment.
The Q3 2018 was the biggest quarter yet, with $3.3B invested across 93 deals during the period.
It has found 2017 to be the record-smashing year for the industry, with the highest amount of venture funding and the most mega deals ($100M+) to date.
And 16% of the 74 companies funded in the quarter are led by women CEOs, up from 11% at the half-year mark.
This spectacular figure was propelled by the record-shattering second quarter, and a record seven deals over $100M.
Five deals were over $50 million, including PatientsLikeMe, Livongo Health, Alignment Healthcare, Nuna Health and Evariant.
The market has experienced an uptick with 13% TTM growth and almost 50% YoY growth (when compared to Q1 2015); it was also the highest Q1 since 2011.
Rock Health argues that digital biomarkers can extend the collection of population level health data and introduce longitudinal data for individual consumers.
Having a balanced number of men and women on leadership teams allows for a diversified set of opinions and perspectives that impact a company's bottom line.